DCVC Bio managing partners Kiersten Stead and John Hamer
September 30, 2024 10:22 AM EDT
Financing
Startups

DCVC Bio reels in $400M third fund

Kyle LaHucik

Senior Reporter

DCVC Bio con­firmed it has put to­geth­er a $400 mil­lion third fund, four years af­ter rais­ing $350 mil­lion in its sopho­more ef­fort …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Po­sei­da shares in­cre­men­tal Phase 1 up­date for Roche-part­nered off-the-shelf CAR-T

Lil­ly-part­nered ra­dio­phar­ma start­up Ak­tis On­col­o­gy rais­es $175M

For some mul­ti­ple myelo­ma pa­tients, Carvyk­ti cut risk of death by 45%

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times